BUFFALO, N.Y., July 20 /PRNewswire-FirstCall/ -- MINRAD International, Inc. (http://www.minrad.com/) has promoted Alejandro Garcia to the position of Managing Director Latin America and Fabiola Currarino to Managing Director Europe. Both Managing Directors will report to Dan McAllister, Vice President International Operations. Ms. Currarino has been with MINRAD since October 2005 when she joined the Company as Area Manager of Latin Europe. In her new position, Ms. Currarino will manage the European markets and will be responsible for hiring four (4) Area Managers and will continue to work out of Madrid, Spain. She came to MINRAD from Systems Support & Services where she was both a Product and Brand Manager. Prior to that, she was Business Development Manager and Marketing Specialist at IBM. Ms Currarino holds a MBA from Harvard Business School and a Bachelor of Business Administration from Pontificia Universidad Catolica Del Peru. Mr. Garcia joined MINRAD in February 2005 and served as its Area Manager in the Mexico, Central American and Caribbean markets. He will continue to work out of Monterrey, Mexico and will have four (4) Latin American Area Managers reporting to him. His previous experience includes marketing management positions at Hasboro, The Trane Company and Frito-Lay. Mr. Garcia holds a MBA from Duke University, Fuqua School of Management in North Carolina, and a Bachelor of Science degree in industrial systems engineering from ITESM in Monterrey, Mexico. About the Company MINRAD International, Inc. is an interventional pain management company with real-time image guidance and anesthesia and analgesia product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, Minrad International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of Minrad International's Form 10-KSB, filed with the Securities and Exchange Commission on March 29, 2006. Although Minrad International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Contact: Dan McAllister, Vice President International Operations of, MINRAD, +1-203-710-6227, or . DATASOURCE: MINRAD International, Inc. CONTACT: Dan McAllister, Vice President International Operations, +1-203-710-6227, or Web site: http://www.minrad.com/

Copyright